Enrollment Starts in Africa CDC-LED Mpox Therapeutic Study (MOSA)
January 15, 2025
Africa CDC, in collaboration with PANTHER and INRB, has launched the MOSA trial in the Democratic Republic of Congo, marking a significant milestone in combating Mpox. With the support of EU funding and Africa CDC leadership, the trial evaluates brincidofovir's safety and efficacy, addressing the urgent need for therapeutics as Mpox cases rise across Africa. Enrolling children and adults in high-risk areas, this adaptive study ensures rapid, evidence-based decision-making. As Africa takes ownership in advancing Mpox research, the MOSA trial reflects a groundbreaking step toward solutions, reinforcing the continent’s leadership in addressing public health challenges through innovative research.
The MOSA trial, spearheaded by Africa CDC in collaboration with PANTHER and the Institut National de Recherche Biomédicale (INRB), represents a landmark moment in the fight against Mpox. Launched at Mbandaka Hospital in the Democratic Republic of Congo, the trial is Africa’s pioneering effort to evaluate therapeutic options for Mpox, particularly brincidofovir, an antiviral developed by Emergent BioSolutions. This adaptive trial design, supported by Horizon Europe funding, underscores the continent's proactive approach in addressing this public health threat.
Declared a Public Health Emergency of Continental Security in 2024, Mpox continues to disproportionately impact vulnerable populations in Africa, including women, children, and individuals living with HIV. Despite the urgent need, no therapeutic has yet been approved for Mpox treatment. Previous studies, including PALM 007 and STOMP, highlighted the limited efficacy of existing treatments, intensifying the demand for innovative solutions.
The MOSA trial is built on rigorous scientific and ethical standards, ensuring rapid decision-making through pre-planned interim analyses. Recruiting both children and adults, it prioritizes those most at risk, particularly in remote regions with limited healthcare access. The trial exemplifies African leadership in research, as stated by Africa CDC Director General Dr. Jean Kaseya: “Africa is not just responding to the Mpox outbreak; we are leading the charge.”
With rising Mpox cases, particularly in the DRC, the MOSA trial aims to generate critical data on brincidofovir’s potential. This collaborative effort not only strengthens Africa’s response to the current crisis but also lays the groundwork for future preparedness. As highlighted by Prof. Samba Ousmane Sow of PANTHER, the initiative reflects the vital role of research in addressing epidemic priorities, reinforcing Africa’s commitment to health innovation and resilience on the global stage.